Bristol-Myers Squibb stock has delivered a 48.8% return over the past year, yet current checks still point to a company that screens as undervalued on both intrinsic value estimates and market multiples.

• The 48.8% one-year return suggests sentiment around Bristol-Myers Squibb has improved markedly, which can compress the margin for error that investors are willing to tolerate.
• Talk of a potential nearly US$400b merger with AstraZeneca may support expectations for a stronger combined drug pipeline, while uncertainty around regulatory scrutiny and shareholder support can weigh on how durable any valuation upside might be.
• On Simply Wall St’s broader valuation checks, Bristol-Myers Squibb is assessed as undervalued in 5 of 6 areas. This points to shares that still lean cheap despite the recent share price strength.

The issue now is whether Bristol-Myers Squibb’s recent climb already reflects its intrinsic value estimate or if the current price still leaves a meaningful discount in place.

Is Bristol-Myers Squibb a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model looks at what Bristol-Myers Squibb’s future cash generation could be worth in today’s money. On this model, the company is working from latest twelve month free cash flow of about $11.5b, with projections that assume broadly stable to slightly declining cash flows over time rather than aggressive growth. That cash flow profile supports an estimated intrinsic value of about $119 per share.

Compared with the current share price, this points to the stock trading at roughly a 46.4% discount to that intrinsic value, so Bristol-Myers Squibb screens as undervalued on this DCF view. Discussion of a potential nearly $400b merger with AstraZeneca helps explain why the price may still sit below the model value, given the extra regulatory and execution risk investors are weighing alongside the cash flow outlook.

Overall, the DCF workup indicates that, on this analysis, Bristol-Myers Squibb stock currently appears undervalued relative to the cash flows analysts expect it to produce.

Our Discounted Cash Flow (DCF) analysis suggests Bristol-Myers Squibb is undervalued by 46.4%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Does Bristol-Myers Squibb Look Undervalued on Earnings?

P/E is a useful yardstick for Bristol-Myers Squibb because earnings power is central to how investors usually compare large pharmaceutical stocks. On this metric, Bristol-Myers Squibb trades on about 14.0x earnings. That sits below the Pharmaceuticals industry average of roughly 15.6x and far below the peer group average near 55.6x.

The Fair P/E Ratio for Bristol-Myers Squibb is estimated at about 18.2x. This is the level that would typically line up with its earnings profile, industry, size and risk characteristics. The current 14.0x multiple is therefore some way under that mark, which suggests the stock is pricing in a discount relative to what this framework would flag as reasonable.

On these P/E comparisons, Bristol-Myers Squibb stock appears undervalued relative to both its estimated Fair P/E and broader peers.

The Bristol-Myers Squibb Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Bristol-Myers Squibb pick up where this valuation puzzle leaves off and spell out what kind of future for growth, margins and earnings would make the stock worth materially more or less than today’s price, using scenarios shared on the Community page. Rather than focus on a single multiple or model output, each Narrative lays out the assumptions behind its fair value so you can compare them with actual results over time.

The Bristol-Myers Squibb community is split between a pipeline led upside story and concern that patent and pricing risks keep the stock closer to fully valued.

Bull case: 20% undervalued

"Breakthrough partnerships such as the BioNTech deal position BMS's pipeline for industry leadership in immuno-oncology and radiopharmaceuticals, with accelerated speed to market and potential first-mover advantage in key tumor types creating a multi-billion dollar opportunity and robust long-term earnings growth…"

Bear case: roughly fairly valued

"Bristol-Myers Squibb is facing significant upcoming patent cliffs, especially for blockbusters like Eliquis (generic in 2028) and Opdivo, raising the risk of generic and biosimilar competition, which could materially impact long-term revenue and earnings growth…"

Do you think there's more to the story for Bristol-Myers Squibb? Head over to our Community to see what others are saying!

The Bottom Line

Bristol-Myers Squibb screens as clearly undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and its earnings multiple, which point in the same direction rather than sending mixed signals. The key question is whether that discount reflects temporary caution or a lasting concern about patent cliffs, execution on the drug pipeline, and any large dealmaking. For you as an investor, the crux is whether Bristol-Myers Squibb can replace at-risk revenues in a way that supports cash flows and justifies a higher multiple over time, or whether the current gap simply prices in those real risks accurately.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.